Xiao Huang
Director/Board Member at CUTIA THERAPEUTICS
Xiao Huang active positions
Companies | Position | Start | End |
---|---|---|---|
CUTIA THERAPEUTICS | Director/Board Member | 26/08/2020 | - |
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Director/Board Member | - | - |
Shanghai Yunfeng Investment Management Co. Ltd.
Shanghai Yunfeng Investment Management Co. Ltd. Investment ManagersFinance Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China. | Corporate Officer/Principal | 01/05/2015 | - |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Director/Board Member | - | - |
MicroPort Cardiac Rhythm Management International Ltd.
MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Director/Board Member | 28/04/2020 | - |
CBMG Holding AB | Director/Board Member | 01/02/2021 | - |
Career history of Xiao Huang
Training of Xiao Huang
Tsinghua University | Undergraduate Degree |
Yale University | Doctorate Degree |
Statistics
International
China | 6 |
United States | 2 |
Hong Kong | 2 |
Operational
Director/Board Member | 5 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Finance | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
CUTIA THERAPEUTICS | Health Technology |
Private companies | 5 |
---|---|
Cutia Therapeutics (Shanghai) Co., Ltd.
Cutia Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Cutia Therapeutics, Cutia Therapeutics (Shanghai) Co., Ltd. develops therapeutics to treat severe facial acne vulgaris. The company is based in Shanghai, China. The Chinese company was founded in 2019. The CEO is Le Le Zhang. | Health Technology |
Shanghai Yunfeng Investment Management Co. Ltd.
Shanghai Yunfeng Investment Management Co. Ltd. Investment ManagersFinance Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China. | Finance |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |
MicroPort Cardiac Rhythm Management International Ltd.
MicroPort Cardiac Rhythm Management International Ltd. Financial ConglomeratesFinance MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong. | Finance |
CBMG Holding AB |
- Stock Market
- Insiders
- Xiao Huang
- Experience